Search

Your search keyword '"F. E. Nathan"' showing total 54 results
Start Over Author "F. E. Nathan"
54 results on '"F. E. Nathan"'

51. Antiandrogen Withdrawal Syndrome With Nilutamide

Author

Mohamed Ismail, Leonard G. Gomella, and F. E. Nathan

Subjects
medicine.medical_specialty, medicine.drug_class, business.industry, Urology, Nilutamida, Antiandrogen, Endocrinology, Internal medicine, Nilutamide, medicine, Prostate disease, Withdrawal syndrome, business, medicine.drug
Published
1997

53. GM-CSF and Accelerated Hemolysis

Author

F E Nathan and E C Besa

Subjects
Text mining, business.industry, Immunology, medicine, MEDLINE, General Medicine, medicine.disease, business, Hemolysis, Lymphoma
Published
1992

54. An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227)

Author

Luis Paz-Ares, Christopher T. Harbison, Prabhu Bhagavatheeswaran, Matthew D. Hellmann, Julie R. Brahmer, Suresh S. Ramalingam, Martin Reck, F. E. Nathan, and Kenneth J. O'Byrne

Subjects
Pharmacology, Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, Immunology, Ipilimumab, Bioinformatics, Recurrent Non-Small Cell Lung Cancer, Internal medicine, Poster Presentation, medicine, Molecular Medicine, Immunology and Allergy, In patient, Nivolumab, Open label, business, Stage iv, Chemotherapy naive, medicine.drug
Abstract

Meeting abstracts Patients with advanced NSCLC are treated with first-line PT-DC, which is associated with a median OS of 8–10 months and 1-year and 2-year survival rates of 30–40% and 10–15%, respectively. Nivolumab (a fully human IgG4 anti-programmed death-1 immune checkpoint inhibitor

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results